On December 23, 2022, OrbusNeich Medical Group Holdings Limited ("OrbusNeich") (06929.HK) was successfully listed on the Main Board of the Stock Exchange of Hong Kong. The global offering of 54,630,000 shares of OrbusNeich Medical was made at an issue price of HK$8.80 per share, raising total proceeds of approximately HK$481 million.

 

OrbusNeich, founded in 2001, is a leading global medical device manufacturer specialized in interventional instruments for percutaneous coronary intervention (PCI) and percutaneous transluminal angioplasty (PTA) procedures. Its main products are balloons and stents for PCI (coronary artery) and PTA (peripheral vascular) procedures, and its products are currently sold in 70 countries and regions.

 

Headquartered in Hong Kong, OrbusNeich is a global medical device manufacture specialized in interventional instruments for percutaneous coronary intervention (PCI) and percutaneous transluminal angioplasty (PTA) procedures.  The company owns more than 180 granted patents globally across key jurisdictions, including 31 in the U.S. and 56 in the PRC.  The company is among the top six players in PCI balloon markets in terms of sales volume in multiple countries including China, Japan, the U.S., and Europe.

 

CICC and CCB International acted as joint sponsors for the IPO, with Fangda Partners and Baker & McKenzie as its PRC legal counsel and Hong Kong and US legal counsel, respectively.

 

King & Wood Mallesons, O'Melveny & Myers acted as counsel to the issuer, advising OrbusNeich on PRC law, Hong Kong and US law respectively. Herbert Smith Freehills, Stibbe advised the issuer on international sanctions law and Dutch law relating to investigations, respectively.